One dose fits all? An analysis of the levodopa equivalent dose over time in Parkinson’s disease
Objective: To ascertain and delineate the differences in Levodopa Equivalent Dose (LEDD) among Parkinson’s disease (PD) subtypes and to examine its evolution over the disease’s…A comprehensive at-home and in-hospital work-up of patients with Parkinson’s disease receiving fosflevodopa/fosfcarbidopa continuous subcutaneous infusion
Objective: Continuous infusion of fosflevodopa/foscarbidopa is a promising treatment for patients with Parkinson’s disease (PD) and severe motor fluctuations unresponsive to conventional therapy. Patient selection…The LRRK2 I1371V mutation alters membrane dynamics and inflammatory profile of astrocytes differentiated from LRRK2-I1371V PD Patient iPSCs
Objective: To evaluate the membrane dynamics and inflammatory profile of astrocytes differentiated from LRRK2-I1371V PD iPSCs in the presence and absence of extracellular α-Synuclein. Background:…Rationale for LRRK2 inhibition in sporadic Parkinson’s disease and the LUMA trial
Objective: To summarize the rationale for LRRK2 inhibition in sporadic PD patients without LRRK2 mutations, and to describe the current design of the LUMA study,…Age and Parkinson’s disease: clinical and biomarkers profiling of younger and older patients
Objective: Given the well-known clinical differences and natural history of Parkinson's disease (PD) according ot patients age, wthis study aims at exploring the different pathophysiological…Metabolic characteristics of brain network in patients with Parkinson’s disease after Deep brain stimulation
Objective: The purpose of this study is to observe the short-term brain metabolic network characteristics of Parkinson's disease patients after STN DBS treatment through PET-CT…Connectivity Profile for Increased Apathy Following Subthalamic Nucleus Deep Brain Stimulation in Parkinson’s Disease
Objective: To describe the structural connectivity profile associated with apathy following subthalamic nucleus (STN) deep brain stimulation (DBS) in Parkinson’s disease (PD). Background: While STN-DBS…Ultrasonography Markers in Prodromal Parkinson’s Disease
Objective: This study aims to investigate ultrasonography markers as a potential imaging marker in prodromal Parkinson's disease, with the goal of identifying individuals at higher…AI based longitudinal changes in substantia nigra contrast and volume on neuromelanin MRI and its relation to clinical markers in a multi-site Parkinson’s disease study.
Objective: To apply an AI model in a multi-site longitudinal study to segment substantia nigra pars compacta (SNpc), perform longitudinal analysis, and quantify its association…Cerebral vasoreactivity in patients with Parkinson’s disease and Diabetes Mellitus
Objective: To assess the relationship between loss of CVR and T2DM in patients with Idiopathic PD. Background: The relationship between cerebral vascular disease (CVD) and…
- « Previous Page
- 1
- …
- 79
- 80
- 81
- 82
- 83
- …
- 338
- Next Page »